Ibandronate sodium and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is found among people who take Ibandronate sodium, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Ibandronate sodium and have Agranulocytosis. It is created by eHealthMe based on reports of 2,870 people who have side effects when taking Ibandronate sodium from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Dec, 15, 2022

2,870 people reported to have side effects when taking Ibandronate sodium.
Among them, 40 people (1.39%) have Agranulocytosis.

What is Ibandronate sodium?

Ibandronate sodium has active ingredients of ibandronate sodium. It is often used in osteoporosis post-menopausal. eHealthMe is studying from 2,903 Ibandronate sodium users for its effectiveness, alternative drugs and more.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 3,145 drugs and 3,366 conditions by eHealthMe.

Number of Ibandronate sodium and Agranulocytosis reports submitted per year:

Could Ibandronate sodium cause Agranulocytosis?

Time on Ibandronate sodium when people have Agranulocytosis *:

Gender of people who have Agranulocytosis when taking Ibandronate sodium *:

female: 94.87 %
male: 5.13 %

Age of people who have Agranulocytosis when taking Ibandronate sodium *:

Common drugs people take besides Ibandronate sodium *:

Common side effects people have besides Agranulocytosis *:

Metastases To Bone (cancer spreads to bone): 16 people, 40.00%
Fever: 14 people, 35.00%
Bone Pain: 13 people, 32.50%
C-Reactive Protein Increased: 12 people, 30.00%
Thrombocytopenia (decrease of platelets in blood): 12 people, 30.00%
Red Blood Cell Count Decreased: 10 people, 25.00%
Renal Impairment (severely reduced kidney function): 10 people, 25.00%
Haemoglobin Decreased: 9 people, 22.50%
Upper Respiratory Tract Infection: 9 people, 22.50%
White Blood Cell Count Increased: 8 people, 20.00%

Common conditions people have *:

Breast Cancer: 12 people, 30.00%
Upper Respiratory Tract Infection: 8 people, 20.00%
Breast Cancer Metastatic: 3 people, 7.50%
Pain: 2 people, 5.00%
Osteoporosis (bones weak and more likely to break): 2 people, 5.00%
Breast Cancer Female: 2 people, 5.00%
Multiple Myeloma (cancer of the plasma cells): 2 people, 5.00%
High Blood Pressure: 2 people, 5.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 2.50%
Diabetes: 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Ibandronate sodium and have Agranulocytosis?

Check whether Agranulocytosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

Related studies

Browse all side effects of Ibandronate sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Agranulocytosis treatments and more:

Agranulocytosis (180,980 reports)

COVID vaccines that are related to Agranulocytosis:

Common drugs associated with Agranulocytosis:

All the drugs that are associated with Agranulocytosis:

Agranulocytosis (3,145 drugs)

Common conditions associated with Agranulocytosis:

Multiple myeloma: 9,913 reports
Breast cancer: 5,558 reports
High blood pressure: 5,100 reports
Schizophrenia: 4,907 reports
Non-hodgkin's lymphoma: 3,585 reports

All the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,366 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibandronate sodium (the active ingredients of Ibandronate sodium) and Ibandronate sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.